Small Molecules in Oncology

1. Front Matter

   Pages i-xvi

   PDF

2. Imatinib Mesylate

   • Cornelius F. Waller

   Pages 1-25

3. Dasatinib

   • Markus Lindauer, Andreas Hochhaus

   Pages 27-65

4. Nilotinib

   • Benjamin N. Ostendorf, Philipp le Coutre, Theo D. Kim, Alfonso Quintás-Cardama

   Pages 67-80

5. Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor

   • Susanne Isfort, Gunhild Keller-v. Amsberg, Philippe Schafhausen, Steffen Koschmieder, Tim H. Brümmendorf

   Pages 81-97

6. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

   • Julius Wehrle, Heike L. Pahl, Nikolas von Bubnoff

   Pages 99-107

7. Erlotinib

   • M. Steins, M. Thomas, M. Geißler

   Pages 109-123

8. Lapatinib

   • Minna Nolting, Tanja Schneider-Merck, Martin Trepel

   Pages 125-143

9. Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer

   • Jens Hasskarl

   Pages 145-164

10. Sunitinib in the Treatment of Advanced Solid Tumors

    • Amal Imbulgoda, Daniel Y. C. Heng, Christian Kollmannsberger

    Pages 165-184

11. Regorafenib

    • Thomas J. Ettrich, Thomas Seufferlein

    Pages 185-196

12. Crizotinib

    • David F. Heigener, Martin Reck

    Pages 197-205

13. Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor

    • Carsten Grüllich

    Pages 207-214

14. Vemurafenib

    • Claus Garbe, Sail Abusaif, Thomas K. Eigentler

    Pages 215-225

15. Dabrafenib

    • Radhika Kainthla, Kevin B. Kim, Gerald S. Falchook

    Pages 227-240

16. Trametinib

    • Robert Zeiser

    Pages 241-248

17. Ruxolitinib

    • Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff, Ralph Wäsch

    Pages 249-257

18. Ibrutinib

    • Mark-Alexander Schwarzbich, Matthias Witzens-Harig

    Pages 259-267

19. Decitabine

    • Björn Hackanson, Michael Daskalakis

    Pages 269-297

20. 5-Azacytidine/5-Azacitidine

    • Antonia M. S. Müller, Mareike Florek

    Pages 299-324

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

• Molecular mechanisms of cancer
• Oncogenic protein kinase inhibitors
• Targeted therapy
• Treatment of malignant diseases

“The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). … This book provides important practical information on a wide variety of novel small molecule-based treatment approaches.” (George Somlo, Doody's Book Reviews, April, 2015)

• Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

  Uwe M. Martens

Policies and ethics